Cue Biopharma Expands Anti-IgE Pipeline in $691M Deal
Boston, USA | April 30, 2026 Cue Biopharma has entered into a strategic licensing agreement with Ascendant Health Sciences...
cGxPwire Editor
Advertisement
Eton Pharmaceuticals Relaunches HEMANGEOL for Infants
DEER PARK, Illinois, May 1, 2026 Eton Pharmaceuticals, Inc. announced the relaunch of HEMANGEOL® (propranolol) oral solution, the only...
MapLight Therapeutics Completes Phase 2 CNS Trials Enrollment
SAN FRANCISCO & BOSTON, May 1, 2026 MapLight Therapeutics, Inc. announced the completion of enrollment in its Phase 2...
Neurocrine CRENESSITY Shows 2-Year Pediatric Benefits
San Diego, USA | May 1, 2026 Neurocrine Biosciences has reported new two-year Phase 3 clinical data for CRENESSITY®...
Sonire Therapeutics Launches U.S. HIFU Trial in Cancer
PALO ALTO, California, May 1, 2026 Sonire Therapeutics Inc. announced the initiation of its first U.S. clinical trial, SUNRISE-II,...
Advertisements
Arrowhead REDEMPLO siRNA Drug Approved in Australia
Pasadena, USA | May 1, 2026 Arrowhead Pharmaceuticals has received approval from Australia’s Therapeutic Goods Administration (TGA) for REDEMPLO®...
Alcresta Therapeutics Shows RELiZORBneo Benefit Data
WALTHAM, Massachusetts, May 1, 2026 Alcresta Therapeutics, Inc. announced the publication of preclinical data evaluating its RELiZORBneo cartridge in...
Viatris Low-Dose Estrogen Patch Phase 3 Data Update
Pittsburgh, USA | May 1, 2026 Viatris has announced multiple clinical data presentations for its investigational low-dose estrogen combined...
LEO Pharma Acquires Replay to Boost Gene Therapy
Ballerup, Denmark | April 30, 2026 LEO Pharma has announced a definitive agreement to acquire Replay, significantly expanding its...
Guardant Health, Nuvalent Partner in Precision Oncology
Palo Alto, USA | April 30, 2026 Guardant Health and Nuvalent have announced a multi-year strategic collaboration to develop...
Advertisement
